Sai Parenteral's IPO Opens Muted
Analysis based on 6 articles · First reported Mar 18, 2026 · Last updated Mar 24, 2026
The IPO of Sai Parenterals Private Limited aims to raise significant capital for expansion and R&D, which could boost its market position in the pharmaceutical sector. However, the muted initial investor response and zero grey market premium suggest a cautious market sentiment, potentially leading to a stable or slightly undervalued listing for Sai Parenterals Private Limited shares on the National Stock Exchange of India and JSE Limited.
Sai Parenterals Private Limited, a diversified pharmaceutical formulations company, launched its Initial Public Offering (IPO) on March 24, 2026, with a price band of ₹372 to ₹392 per share, aiming to raise ₹408.79 crore. The IPO consists of a fresh issue of ₹285 crore and an Offer for Sale (OFS) of ₹123.79 crore, with existing shareholders like Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, and others divesting stakes. The company plans to use the proceeds for capacity expansion, establishing a new R&D centre, debt repayment, working capital, and investing in its Singapore subsidiary to acquire NovoMed Pharmaceuticals Limited in Australia. Arihant Capital Markets is the lead manager, and Bigshare Services Private Limited is the registrar. Despite raising ₹122.6 crore from anchor investors, the IPO received a muted response on Day 1, with a subscription of only 0.05 times and a grey market premium of ₹0, indicating a likely listing at the IPO price on the National Stock Exchange of India and JSE Limited.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard